Protara Therapeutics (TARA) Total Current Liabilities (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Total Current Liabilities data on file, last reported at $8.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 27.13% year-over-year to $8.9 million in Q1 2026; TTM through Mar 2026 was $8.9 million, a 27.13% increase from a year earlier, with the FY2025 full-year figure at $10.9 million, changed 0.2% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $8.9 million, down from $10.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for TARA reached as high as $11.0 million in Q4 2024 and fell as low as $2.9 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $6.9 million across 5 years, with a median of $6.4 million in 2023.
• Across the five-year window, Total Current Liabilities soared 124.05% in 2023 and retreated 14.18% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $5.7 million in 2022, then rose by 7.13% to $6.1 million in 2023, then soared by 78.26% to $11.0 million in 2024, then slipped by 0.2% to $10.9 million in 2025, then dropped by 18.44% to $8.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $8.9 million in Q1 2026, $10.9 million in Q4 2025, and $9.9 million in Q3 2025.